HC Wainwright Has Positive Opinion of TARA FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Protara Therapeutics to a loss of $1.35 per share from a projected loss of $1.38, versus the analyst consensus loss of $1.40.
• Protara reported a quarterly loss of $0.35 per share, beating analysts’ estimate of a $0.37 loss by $0.02.
• Shares opened at $2.43, down 3.2%; analysts’ average rating is “Moderate Buy,” with an average price target of $26.25.

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Stock analysts at HC Wainwright increased their FY2026 earnings per share estimates for Protara Therapeutics in a research note issued to investors on Monday, November 9th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($1.35) for the year, up from their previous forecast of ($1.38). The consensus estimate for Protara Therapeutics' current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Protara Therapeutics' Q4 2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.34) EPS, Q2 2027 earnings at ($0.34) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.34) EPS, FY2027 earnings at ($1.37) EPS and FY2028 earnings at ($0.41) EPS.

Several other equities research analysts also recently weighed in on TARA. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Cantor Fitzgerald reissued an "overweight" rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Finally, Wall Street Zen upgraded Protara Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, September 5th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Protara Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $26.25.

Protara Therapeutics Stock Down 3.2%

Shares of Protara Therapeutics stock opened at $2.43 on Wednesday. Protara Therapeutics has a twelve month low of $2.09 and a twelve month high of $7.82. The company has a fifty day moving average price of $2.97 and a 200 day moving average price of $4.46.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.02.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TARA. Fisher Asset Management LLC boosted its holdings in Protara Therapeutics by 30.2% in the third quarter. Fisher Asset Management LLC now owns 129,612 shares of the company's stock worth $395,000 after purchasing an additional 30,046 shares during the period. Alps Advisors Inc. boosted its holdings in shares of Protara Therapeutics by 36.3% in the 3rd quarter. Alps Advisors Inc. now owns 77,735 shares of the company's stock valued at $237,000 after buying an additional 20,694 shares during the period. WINTON GROUP Ltd boosted its holdings in shares of Protara Therapeutics by 16.7% in the 2nd quarter. WINTON GROUP Ltd now owns 32,800 shares of the company's stock valued at $125,000 after buying an additional 4,700 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Protara Therapeutics during the 2nd quarter valued at about $69,000. Finally, Corient Private Wealth LP bought a new stake in shares of Protara Therapeutics during the 2nd quarter valued at about $41,000. Institutional investors and hedge funds own 38.13% of the company's stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company's lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer. Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.